FINWIRES · TerminalLIVE
FINWIRES

Update: Mizuho Securities Keeps Price Target on Harmony Biosciences to $50, Maintains Outperform Rating

作者

-- (Updated to keep price target unchanged).

Harmony Biosciences (HRMY) has an average rating of overweight and mean price target of $43, according to analysts polled by FactSet.

(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

Price: $31.09, Change: $-0.07, Percent Change: -0.22%

相關文章